Results 91 to 100 of about 8,846,368 (309)

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

open access: yesMolecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute   +17 more
wiley   +1 more source

Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells

open access: yesMolecular Oncology, EarlyView.
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller   +17 more
wiley   +1 more source

On the Binary Input Gaussian Wiretap Channel with/without Output Quantization

open access: yesEntropy, 2017
In this paper, we investigate the effect of output quantization on the secrecy capacity of the binary-input Gaussian wiretap channel. As a result, a closed-form expression with infinite summation terms of the secrecy capacity of the binary-input Gaussian
Chao Qi, Yanling Chen, A. J. Han Vinck
doaj   +1 more source

Digital to analog conversion apparatus [PDF]

open access: yes, 1973
A digital to analog converter which improves the accuracy of reconstruction of a sampled analog signal without requiring that the sampling rate of the original signal be increased to obtain such ...
Dotson, W. P., Jr.
core   +1 more source

ATF4‐mediated stress response as a therapeutic vulnerability in chordoma

open access: yesMolecular Oncology, EarlyView.
We screened 5 chordoma cell lines against 100+ inhibitors of epigenetic and metabolic pathways and kinases and identified halofuginone, a tRNA synthetase inhibitor. Mechanistically halofuginone induces an integrated stress response, with eIF2alpha phosphorylation, activation of ATF4 and its target genes CHOP, ASNS, INHBE leading to cell death ...
Lucia Cottone   +11 more
wiley   +1 more source

Quaternion Signal Analysis for Detection of Broken Rotor Fault Degrees in Induction Motors

open access: yesApplied Sciences
Fault detection in induction motors is essential for maintaining the reliability of industrial operations. In practical applications, induction motors experience gradual wear on critical components, such as rotor bars, affecting their performance.
Jose Luis Contreras-Hernandez   +3 more
doaj   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

open access: yesMolecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg   +43 more
wiley   +1 more source

Random Filters for Compressive Sampling [PDF]

open access: yes, 2007
This paper discusses random filtering, a recently proposed method for directly acquiring a compressed version of a digital signal. The technique is based on convolution of the signal with a fixed FIR filter having random taps, followed by downsampling ...
Tropp, Joel A.
core  

Digital Signal Processing [PDF]

open access: yes, 1980
Contains research objectives and reports on sixteen research projects.U.S. Navy - Office of Naval Research (Contract N00014-75-C-0852)National Science Foundation FellowshipNational Science Foundation (Grant ENG76-24117)U.S.
Baggeroer, Arthur B.   +19 more
core   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

open access: yesMolecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy